News | February 24, 2011

New Zealand Hospital Shortens Prostate Cancer Treatment Times

February 24, 2011 – A cancer center in New Zealand has acquired several technology solutions that lets it cut prostate cancer treatment times in half per session. Clinicians at St. George's Cancer Care Centre in Christchurch, New Zealand, use Elekta technology to deliver prostate therapy.

Patients with prostate cancer typically are required to lie still for seven to eight minutes with a full bladder during a therapy session, a process repeated 37 times over a treatment course.

"We used a single non-stop arc of the radiation beam and just under three minutes of actual therapy time," said David McKay, principal physicist at St. George's. His is the second center in Australasia to use Elekta VMAT. “He is about three-quarters of the way through his treatment course and is doing very well."

The cancer center acquired two Elekta Synergy linear accelerators, Monaco treatment planning for Elekta VMAT and Mosaiq oncology information system.

"We wanted to offer the best possible treatment to our patients by using the most advanced technology available," MaKay said. "Elekta offered a full package that included the planning system, record-and-verify system and the linear accelerator. It was very appealing that we could get all that from one provider. It helps if the planning system and accelerator come from the same vendor – so that technology improvements in the linac are then reflected in the planning system more quickly. The communication between Mosaiq and the treatment planning and therapy systems also is critical to streamline information flow."

Since its first patient, St. George's has started its second prostate cancer patient on the therapy. For both patients, VMAT planned with Monaco has been successful, McKay said.

"The plans compare favorably with our IMRT plans, and using Monaco planning for the second patient, we developed a plan that shifted the radiation dose somewhat better around the rectum, which helped us avoid exposing it to an above-tolerance dose. The doctors were very pleased with that," he said. "Additionally, the Monte Carlo dose algorithm improves our ability to calculate the final patient dose, which helps us deliver the highest therapeutic dose confidently."

The Elekta Symmetry enables clinicians to reduce margins, account for baseline shifts and employ uninterrupted treatment delivery while the patient breathes freely.

Anticipating a greater volume of patients with lung cancer at the clinic, a team of clinicians, physicists and radiation therapists at St. George's has begun evaluating the 4-D imaging capabilities of Symmetry in select lung cancer patients.

"In a recent case, the radiation oncologist had created some standard margins around a tumor of a lung cancer patient scheduled for palliative treatment," McKay recalls. "We did a scan to observe the tumor motion and confirm the margins were satisfactory. We were quite surprised at how much movement the 4-D acquisition revealed in this case. The margins were just about adequate to cover the volume, but if there had been just a little bit more movement we would have had to re-plan the case. It was eye-opening. The 4-D capability is a useful feature that will help ensure the highest standard of care for our patients."

For more information: www.elekta.com

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...